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ABSTRACT 
Telomerase is a ribonucleoprotein enzyme maintaining telomere length. Telomerase reverse 
transcriptase (TERT), which acts as a catalytic unit, is tightly repressed in differentiated 
human cells while activated in cancer cells for telomere lengthening. Beyond that, TERT has 
also been shown to contribute to oncogenesis via its telomere lengthening-independent 
functions. This thesis is designed to define the role of TERT in oncogenesis and the 
biological implications of the genetic alterations in the TERT gene/promoter. 
The first paper was focused on the role of TERT in acute myeloid leukemia (AML) therapy 
targeting mutations of FMS-like tyrosine kinases 3 (FLT3). The internal tandem duplication 
(ITD) mutation in the juxtamembrane domain in the FLT3 gene has been reported as one of 
the most frequent mutations in AML, and PKC412 was developed as its specific inhibitor. 
We observed that in FLT3ITD-harboring primary cells from AML patients and AML cell 
lines, PKC412 down-regulated TERT expression and telomerase activity in a MYC-
dependent manner. Moreover, TERT restored the activity of FLT3 downstream effectors and 
alternative tyrosine kinase signaling pathways inhibited by PKC412, thereby attenuating 
PKC412-mediated apoptosis of leukemic cells. Taken together, FLT3ITD regulates TERT 
expression via a MYC-dependent manner, and TERT down-regulation is required for 
PKC412-mediated anti-AML efficacy. 
The recurrent TERT promoter mutations have been demonstrated to stimulate TERT 
transcription by generating new E26 transformation-specific (ETS)-binding sites in different 
human malignancies. Furthermore, rs2736098 and rs2736100, the two single nucleotide 
polymorphisms (SNPs) in the TERT locus, have been reported to associate with cancer 
susceptibility. In paper II, we found that compared to hepatocellular carcinoma (HCC) 
patients with wild type TERT promoter or healthy controls, a significant difference in these 
two genotypes was present in patients carrying TERT promoter mutations. We observed a 
negative association between TERT promoter mutations and rs2736098_TT and 
rs2736100_CC genotypes. There was no association between TERT promoter mutations and 
clinico-pathological variables or CTNNB1 mutations. In summary, the germline TERT 
rs2736098 and rs2736100 polymorphisms may play a role in TERT promoter mutation 
occurrence in HCC. 
The dysregulation of DNA methyltransferases (DNMTs) and the aberrant DNA methylation 
is a cancer hallmark. In paper III, we showed that TERT up-regulated DNA 
methyltransferase 3B (DNMT3B) expression and thereby contributing to the repression of 
downstream tumor suppressors as well as the activation of AKT. We found a positive 
correlation between TERT and DNMT3B expression in both HCC cell lines and primary 
HCC tumors. Mechanistically, TERT promotes DNMT3B transcription by cooperating with 
the transcription factor (TF) Sp1. The depletion of TERT expression led to significant 
demethylation in the tumor suppressor PTEN promoter and a reduced global DNA 
methylation by down-regulating DNMT3B expression. The restoration of PTEN expression 
mediated by TERT depletion inhibited AKT activity. Higher levels of TERT and DNMT3B 
expression predicted a significantly shorter survival in HCC patients according to analysis of 
The Cancer Genome Atlas (TCGA) dataset. Taken together, we identified the TERT-
DNMT3B-PTEN-AKT axis in HCC cells, which promotes HCC progression via aberrant 
DNA methylation. 
In conclusion, our studies demonstrated the effect of genetic alterations on TERT/telomerase 
activation, and the novel telomere lengthening-independent roles of TERT in carcinogenesis, 
which should be implicated in cancer therapy/precision oncology. 
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1 INTRODUCTION 
 
1.1 Telomere and telomerase 
1.1.1 Telomere 
1.1.1.1 Structure 
The telomere is a protective complex consisting of tandem DNA repeats at chromosome 
ends. The repeated sequence is TTAGGG (G-rich strand 5‟ –3‟) and the length varies 
widely among different eukaryotic species. In human the length of repeats ranges between 
8 and 15kb. Telomeric DNA is double-stranded DNA (dsDNA) with a 3‟ single-stranded 
overhang. The tail functions not only as a primer for telomerase, but also as a binding place 
for specific protective proteins [1]. The telomeric single-stranded DNA (ssDNA) usually 
inserts into the dsDNA and forms a T-loop, protecting the chromosome end [2]. 
1.1.1.2 Telomere-binding proteins 
Telomeric DNA is capped by a protein complex known as shelterin, which includes 
repressor and activator protein 1 (RAP1 or TERF2IP), protection of telomeres 1 (POT1) 
and TPP1 (also known as ACD), telomeric repeat-binding factor 1 (TRF1 or TERF1), TRF2 
(also known as TERF2), TRF1-interacting nuclear protein 2 (TIN2 or TINF2). TRF1 and 
TRF2 bind to double-stranded telomeric DNA while TPP1 and POT1 bind to the single-
stranded tail. They connect to each other by the bridging component TIN2. RAP1 is 
associated with TRF2 [2]. 
1.1.1.3 Telomere function 
The telomere serves two key functions. First, it protects the chromosome by preventing the 
ssDNA from being recognized as a broken end or an end-to-end fusion. Otherwise the 
processes including DNA end-joining, DNA recombination, and DNA repair would result 
in unstable chromosomes. Second, the general chromosome replication process cannot 
cover the ends (so-called the end-replication problem), which leads to attrition of the 
telomere. This problem can be resolved by telomerase, which adds TTAGGG repeats at the 
end of chromosomes. However, most human cells lack or only have very limited telomerase 
activity, and therefore the telomere is shortened along with cell division. Cells would stop 
dividing when the shortened telomere reaches a critical size [3]. Thus, the telomere-
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shortening process works as a mitotic clock, counting the number of cell replications and 
thereby conferring limited lifespan to somatic cells. 
1.1.2 Telomerase  
Telomerase is a cellular ribonucleoprotein enzyme consisting of two core subunits, 
telomerase reverse transcriptase (TERT) and telomerase RNA (TERC). The TERT subunit 
provides the active site for catalysis whereas TERC functions as a RNA template for 
telomeric DNA synthesis. Studies have revealed that TPP1 plays a central role in recruiting 
telomerase to chromosome ends by binding to TERT. After recruiting, telomerase elongates 
the telomere by forming a product-template duplex and recycling of the internal template 
[4]. Beyond TERT and TERC, some auxiliary components are also necessary when 
telomerase functions in vivo, including dyskerin (DKC), NHP2 ribonucleoprotein (NHP2), 
NOP10 ribonucleoprotein (NOP10), GAR1 ribonucleoprotein homolog (yeast) (GAR1), 
reptin and pontin (Figure 1) [5].  
  
Figure 1. Shelterin complex and telomerase. 
1.1.3 Telomerase reverse transcriptase (TERT) 
While TERC is ubiquitously expressed in human cells, TERT expression is tightly limited 
to stem/progenitor cells, activated lymphocytes and other cells with high proliferation 
potentials, which indicates a rate-limiting role of TERT in controlling telomerase activity.  
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1.1.3.1 TERT regulation 
TERT expression can be regulated at both the transcription and posttranslation levels. In 
general, the regulation of TERT transcription is crucial, and posttranslational modification 
is also responsible for controlling telomerase activity [6]. 
1.1.3.1.1 Transcription factors (TFs) and TERT expression 
At the level of transcription, the TERT promoter is a region containing plenty of consensus 
sequences for TFs, including GC-boxes, E-boxes, ETS and E2F consensus sites, but lacking 
a TATA-box [6]. The most important TF in TERT trans-activation is c-Myc, which binds to 
E-boxes [7]. However, there are also some other E-box binding TFs (Mad1 and USF1) 
repressing TERT expression. Beyond that, some GC-box binding TFs including Sp1 and 
Sp3 are important for the initiation of TERT transcription. In addition, different negative 
regulatory factors might repress TERT transcription by binding to X-box, E2F, MT-box, 
and MZF-2 sites [8].  
1.1.3.1.2 Epigenetic regulation of TERT 
The regulation of TERT promoter activity occurs at multiple levels, and histone 
modification and cytosine-phosphate-guanine (CpG) methylation also play critical roles in 
TERT transcription [8].  
It has been shown that the TERT promoter could be activated by hyperacetylation of core 
histones. Inhibition of class I and II histone deacetylases (HDACs) by trichostatin A could 
induce TERT expression. The increase of methylation at H3K4 resulting from over-
expression of SMYD3 or inhibition of lysine-specific demethylase 1 (LSD1) leads to TERT 
transcription activation [9]. 
CpG methylation is another important part of epigenetic regulation; however, plenty of data 
supported a dual role of methylation in TERT promoter regulation. On the one hand, 
treatment of immortal fibroblast line with the demethylating agent 5-aza-2'-deoxycytidine 
resulted in increased TERT transcription, which indicated that promoter methylation could 
lead to TERT promoter repression. On the other hand, a CpG island locating across the 
TERT promoter and 5‟ end of the TERT gene is usually methylated in human cancer cells, 
and demethylation in some cancer cell lines resulted in the decrease of TERT expression. 
This is probably because some binding sites of transcriptional repressors are blocked by 
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CpG methylation, which suggests that CpG methylation can promote TERT transcription in 
cancer cells [9]. 
1.1.3.1.3 Posttranslational regulation of TERT expression 
The posttranslational modification of TERT is mainly composed of two parts: the 
phosphorylation of TERT by both protein kinase C (PKC) and AKT/protein kinase B (PKB) 
leads to telomerase activation; ubiquitination by Makorin Ring Finger Protein 1 (MKRN1), 
C terminus of HSC70-Interacting Protein (CHIP), and Hdm2 E3 ligases results in a 
telomerase activity decrease [6]. 
1.1.3.2 TERT promoter mutations 
1.1.3.2.1 Function of TERT promoter mutations 
Besides the TFs mentioned above, ETS TFs are also reported to participate in the TERT 
expression regulation. Interestingly, most cancer-associated TERT promoter mutations 
function by generating de novo ETS binding sites. Two major mutations are -124C/T and -
146C/T, which are named C228T and C250T, respectively. These two mutations generate 
putative ETS-binding sites (TTCC), thereby activating TERT transcription. Many studies 
support the concept that TERT promoter mutations contribute to tumorigenesis by 
increasing TERT transcription [5]. 
Besides the two major mutations mentioned above, CC-to-TT tandem mutations at -124/-
125bp and - 138/-139bp, and the C-to-T mutation at -57 are also found in a small 
proportion of cancers [5]. 
1.1.3.2.2 TERT promoter mutations in human cancers 
TERT promoter mutations have been identified in several human cancers. Among them, 
bladder, renal pelvic, thyroid, HCC, glioblastoma and melanoma have shown a high 
mutation frequency [10,11]. However, TERT promoter mutations are rare in tumors such as 
prostate and breast cancer and leukemia [12]. 
1.1.3.3 Single nucleotide polymorphisms (SNPs) of the TERT gene and cancer 
susceptibility 
It is known that SNPs are the most common sources of human genetic variations, which 
may contribute to cancer risk. Many studies suggest that SNPs in the TERT gene are 
associated with susceptibility of different cancers [13]. Among the multiple TERT SNPs, 
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the two most studied are rs2736100 at intron 2 and rs2736098 at exon 2. Lung cancer, basal 
cell carcinoma and pancreatic cancer show strong associations with the TERT rs2736100 
CC genotype. Moreover, the association between rs2736098 and cancer risk has also been 
demonstrated in multiple types of cancer including HCC, lung cancer, breast cancer, and 
others [14-16]. 
1.1.3.4 Noncanonical functions of TERT in cancers 
TERT was first recognized for its telomere-lengthening activity. However, over the past 
decade, accumulating data have suggested that TERT can function as a regulator in the 
transcription of genes and therefore contribute to cell survival and proliferation in cancers 
[17-19]. The two well-studied signaling pathways regulated by TERT are the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) and Wnt/β-catenin pathways 
[20,21]. NFκB pathway is critical in cellular and developmental processes, and the key TF 
P65 in this pathway has been reported to stimulate expression of its target genes, most of 
which are involved in inflammation and cancer progression [22,23]. It has been 
demonstrated that P65 can activate TERT by binding to its promoter as well as to TERT 
protein, which promotes TERT nuclear translocation [24,25]. Intriguingly, studies showed 
that the interaction between TERT and P65 could also promote the complex localizing to 
promoters of the NFκB downstream genes, including interleukin (IL)-6, IL-8 and tumor 
necrosis factor-α (TNF-α) [26,27].  Taken together, there might be a positive feedback link 
between TERT and the NFκB signaling pathway, which serves as the mechanism 
underlying chronic inflammation and the development from inflammation to various 
manifest cancers.  
Beyond that, TERT has been demonstrated to play a role in the Wnt/β-catenin pathway. The 
Wnt/β-catenin signaling pathway is the key regulator in organ development in the embryo 
as well as cell fate decision in stem cells, and the constitutive activation of Wnt/β-catenin 
pathway in cells can lead to tumor development [28]. The interaction between TERT and β-
catenin was first indicated in mice. The study demonstrated that TERT could promote the 
activity of Wnt/β-catenin by functioning as a cofactor in the β-catenin transcriptional 
complex and occupying promoters of Wnt/β-catenin downstream genes [29]. Moreover, 
TERT is a direct target of β-catenin, which can regulate TERT transcription by binding to 
the TERT promoter in cancer cells and stem cells [30,31]. Overall, the accumulating 
evidence indicates a feed-forward regulatory cycle between TERT and Wnt/β-catenin 
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pathway, which maintains telomerase activity and stimulates downstream oncogene 
transcription. 
Studies further showed the noncanonical functions of TERT besides cooperating with P65 
and β-catenin. TERT can promote VEGF transcription by acting as a cofactor with TF Sp1 
[32]. It is reported that the interaction between TERT and AKT might also promote 
phosphorylation of each other [33-35].  
1.2 Epigenetics and cancer 
Epigenetics refer to heritable changes of gene expression without alteration of the 
underlying DNA sequence. Epigenetic mechanisms play a crucial role in normal cell 
development and differentiation as well as metastasis and progression of cancer. Epigenetic 
mechanisms mainly consist of histone modification and DNA methylation [36]. 
1.2.1 Histone modification 
The histone is a spool-like highly alkaline protein present in eukaryotic cell nuclei. DNA is 
twisted around the histones and further compacted to form nucleosomes. The histone 
includes five family proteins. Histone 1 and histone 5 are linker proteins, while histones 2, 
3 and 4 are core assembly proteins. Modifications of histones have a direct impact on 
chromatin structure, thereby affecting gene expression. Modifications such as 
ubiquitination, phosphorylation, methylation, and acetylation at N-terminal tails of histones 
can regulate gene activities together with other epigenetic mechanisms [36,37]. 
1.2.2 DNA methylation 
It is well established that DNA methylation plays an essential role in the regulation of gene 
expression [38]. In most cases, DNA methylation occurs at 5th carbon of cytosine in CpG 
dinucleotides. The clusters of CpG are named CpG islands, and they are widely present in 
the human genome, especially at 5‟ regions that consist of promoter and transcription sites. 
Most of the CpG islands are unmethylated or methylated at a very low level in normal cells. 
In contrast, abnormal methylation occurs in most tumor cells. Specific promoter 
hypermethylation can be associated with inactivation of tumor-suppressor genes (TSGs) 
while global hypomethylation have been associated with genomic instability [36]. Silencing 
of TSGs such as PTEN and RASSF1A is achieved by hypermethylation of CpG islands in 
promoter sequences, thereby leading to abnormal expression of downstream genes [38,39]. 
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An increasing number of studies indicate that the aberrant methylation of CpG islands is 
one of the cancer hallmarks [40]. 
It is reported that cellular DNA methylation patterns are established by at least three 
independent DNA (5-cytosine)-methyltransferases (DNMTs): DNMT1, DNMT3A and 
DNMT3B, which are enzymes that methylate the cytosine residue of CpG. DNMT1 
expression is more abundant in somatic cells compared to DNMT3A and DNMT3B. The 
reason might be that DNMT1 usually works as „maintenance‟ methyltransferase. DNMT1 
mainly catalyzes hemi-methylation and maintains the methylation patterns in newly 
replicated DNA fragments. DNMT3 family enzymes are required for the de novo 
methylation of a cytosine residue. DNMT3A and DNMT3B are highly expressed during 
stages when new DNA methylation patterns are being established, such as the blastocyst 
stage and germ cell developing stage [41]. Increasing expression of DNMT1, DNMT3A 
and 3B has been observed in various types of tumors [42]. 
1.3 Hepatocellular carcinoma (HCC) 
1.3.1 Epidemiology 
HCC is the primary malignancy of the liver. Most patients with HCCs are diagnosed in 
developing countries. HCC ranks third in terms of incidence in Eastern and South-Eastern 
Asia, Sub-Saharan Western and Eastern Africa. An estimated number of 466,100 new cases 
and 422,100 deaths occurred in China in 2015, which is almost half of all cases diagnosed 
globally. It was also the third cause of death from cancer worldwide in 2014. HCC is more 
common in males with a male: female ratio of 2.4 worldwide [43]. 
1.3.2 Etiology 
There are multiple risk factors for HCC development; there is a strong association between 
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) and cirrhosis and HCC 
development. The regions with high incidence rates of HCC overlap with the regions where 
HBV and HCV infections are endemic. Around 80%–90% of HCC cases occur in cirrhotic 
livers. Other causes including alpha1-antitrypsin deficiency, hereditary hemochromatosis, 
autoimmune hepatitis, and Wilson‟s disease also play a role in HCC development but are 
less common. In addition, there is an incremental effect of presence of more than one risk 
factor responsible for HCC. And alcohol abuse further increases this risk by synergistic 
interaction with hepatitis virus infections [44,45]. 
  
8 
 
1.3.3 Genetic alterations 
Improved knowledge of oncogenic processes has revealed the genetic alterations and 
signaling pathways involved in HCC tumorigenesis. The most studied ones are the 
RAF/MEK/ extracellular signal-related kinase (ERK) pathway, phosphatidylinositol-3 
kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, insulin-like growth 
factor pathway, WNT/β-catenin pathway, growth factor-regulated angiogenic signaling and 
hepatocyte growth factor/c-MET pathway [46-49]. Moreover, drugs targeting some 
components in these signaling pathways have been developed as therapies for HCC [50,51].  
In addition, TERT and DNA methylation was also found to be important in HCC 
tumorigenesis. Up to 60% of HCC patients carry TERT promoter mutations, and it is 
reported that TERT rs2736100 and rs2736098 are associated with an increased HCC risk 
[15]. Studies have shown that methyltransferases DNMT1 and DNMT3B are up-regulated 
in HCC compared to non-tumorous liver tissues, thereby contributing to HCC by 
suppressing TSGs [42,50]. 
1.4 Acute myeloid leukemia (AML) 
1.4.1 Definition 
Leukemias are clonal disorders characterized by hematopoietic insufficiency due to the 
abnormal proliferation of incompletely matured myeloid or lymphoid cells. Normally, the 
common pluripotent stem cell can differentiate into a lymphoid precursor or a myeloid 
precursor. Based on the origin of the cells and the usual onset and progression of the disease, 
leukemia is classified into four major types: acute lymphocytic leukemia, chronic 
lymphocytic leukemia, AML and chronic myeloid leukemia [52]. 
AML, just as its name implies, is myeloid precursors-derived acute disorder. It can be 
phenotypically and genetically heterogeneous but with a common characteristic of 
abnormal accumulation of blast cells in the bone marrow and peripheral blood. The 
manifestations of AML can be diverse and nonspecific, but most of them are attributed to 
the cytopenias. The leukemic expansion of the bone marrow leads to anemia (fatigue and 
dyspnea), neutropenia (infections) and thrombocytopenia (hemorrhages) [53].  
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1.4.2 Classifications 
Nikolaus Friedreich defined and used the term of “acute leukemia” for the first time in 1857, 
but it was not classified into myeloid and lymphoid until 1877, when polychromatic 
staining was developed by Paul Ehrlich [54]. Afterwards, many ways to classify AML were 
proposed, and the most widely accepted one is the World Health Organization (WHO) 
classification [53,55]. WHO classification not only divides AML according to the 
morphology, but also reflects the genetic and clinical diversity [53]. 
1.4.3 Epidemiology 
1.4.3.1 Incidence 
AML is a relatively rare cancer which represents 1.3% of all new cancer cases in the US 
2017, but it is the most common myeloid leukemia. AML is more common in older adults 
with a median age at diagnosis of 68. Beyond that, the number of new cases is larger among 
men compared to women [56]. AML is one of the most common pediatric cancer with the 
incidence of 7.7 per million children aged 0-14 in the United States [57]. Ethnic origin is 
another strong factor influencing AML incidence. Studies have shown that the incidence of 
AML is much lower in Asia than that in western countries [58]. 
1.4.3.2 Risk factors 
The risk factors contributing to leukemogenesis can be various; however, the most well-
known ones are high-dose ionizing radiation exposure, chronic, high-dose benzene 
exposure, and alkylating chemotherapeutic agents. Most of them function by producing 
oxidative DNA damage [58]. On the other hand, the genetic background, especially the 
susceptibility genes of hematological malignancies shared by first-degree relatives of 
patients increase their risk of similar malignancies [59]. 
1.4.4 Mechanisms/ pathophysiology 
Along with the development of new genomic techniques, next-generation sequencing is 
used to define the genomic landscape of AML as well. TCGA Research Network analyzed 
the genomes of 200 patients with AML and identified nine functional categories of genes 
that are commonly mutated in AML (Table 1) [60]. Among the 23 genes that were 
frequently mutated, three genes were mutated even more frequently than others in AML 
patients: FLT3; DNMT3A and  nucleophosmin (NPM1) [61]. 
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Table 1. Functional Categories of Genes Commonly Affected in AML 
Functional Category Selected Gene Members 
Activated Signaling Kinases (eg, FLT3, KIT), RAS family members (eg, KRAS, NRAS) 
DNA methylation-associated 
genes 
DNMT3A, TET2, IDH1, IDH2 
Myeloid TF gene fusions 
PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1 
Myeloid TF gene mutations 
RUNX1, CEBPA 
Chromatin-modifying genes 
Mutations (eg, ASXL1, EZH2) or KMT2A fusions 
Nucleophosmin (NPM1) gene NPM1 
Tumor-suppressor genes  TP53, WT1, PHF6 
Spliceosome-complex genes  SRSF2, U2AF1 
Cohesin-complex genes  STAG2, RAD21 
Abbreviations: AML, acute myeloid leukemia; TF, transcription factor; ASXL1, additional sex combs-like 
1 transcriptional regulator; CBFB, core-binding factor subunit-β; CEBPA, CCAAT/enhancer-binding 
protein-α; DNMT3A, DNA methyltransferase 3A; EZH2, enhancer of zeste 2 polycomb repressive complex 
2 subunit; FLT3, FMS-related tyrosine kinase 3; IDH, isocitrate dehydrogenase; MYH11, myosin heavy 
chain 11 smooth muscle; NPM1, nucleophosmin; PHF6, PHD finger protein 6; PML, promyelocytic 
leukemia; RARA, retinoic acid receptor-α; RUNX1, Runt-related transcription factor 1; RUNX1T1, RUNX1 
translocated to 1; SRSF2, serine/arginine-rich splicing factor 2; STAG2, stromal antigen 2; TET2, tet 
methylcytosine dioxygenase 2; U2AF1, U2 small nuclear RNA auxiliary factor 1; WT1, Wilms tumor 1. 
 
1.4.5 Treatment 
The primary goal is to achieve complete remission (CR) first and then maintain the CR by 
giving consolidation treatment. CR is defined as less than 5% blasts in the bone marrow, a 
neutrophil count greater than 1.0 × 10
9
 /L, a platelet count more than 100 × 10
9
 /L and 
independence of red cell transfusion [62].   
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The initial phase of the treatment to achieve CR is referred to induction therapy. The general 
therapeutic strategy has almost remained unchanged, which is the combination of continuous-
infusion cytarabine with an anthracycline (eg, daunorubicin, idarubicin, or the 
anthracenedione mitoxantrone) [63,64].  
If CR is achieved after induction therapy, appropriate postremission treatment is essential for 
maintenance. The aim of postremission treatment is to kill leukemic cells remaining in the 
bone marrow or blood. The strategies include intensive chemotherapy and hematopoietic 
stem cell transplantation (HSCT). For patients younger than 60, the standard therapy is 2 to 4 
cycles of intermediate-dose cytarabine, however, the most appropriate number of cycles and 
dose depend on individuals. For older patients, neither more intensive consolidation 
chemotherapy nor less intensive consolidation chemotherapy gives a satisfying outcome, 
which means that the exploration of new maintenance therapies is necessary [65-69].  
HSCT is known as the most successful curative treatment. Based on the different level of risk 
in patients, autologous HSCT or allogeneic HSCT can be the option.  While autologous 
HSCT is not recommended in patients with high-risk cytogenetics, allogeneic HSCT can 
offer a relatively satisfying outcome in patients with intermediate- and high-risk AML 
[70,71]. 
1.5 FMS-like tyrosine kinase3 (FLT3) in AML 
1.5.1 FLT3 mutations in AML 
FLT3 is a gene located on chromosome 13q12 encoding the FLT3 tyrosine kinase receptor, 
which falls into Class III receptor tyrosine kinase [72,73]. The other members in this class are 
platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KIT), and 
macrophage colony-stimulating factor receptor (FMS). Activation of FLT3 by ligand (FL) 
promotes cell proliferation through downstream pathways, including PI3K, AKT, RAS, ERK 
and mTOR [74]. However, mutations can result in constitutive activation of the receptor even 
without ligand.  The internal tandem duplication (ITD) mutation in the FLT3 gene has been 
reported as one of the most frequent mutations in AML, which occurs in 20% -30% of AML 
patients and is associated with poor prognosis [75]. Single base mutation in the tyrosine 
kinase domain (TKD) of FLT3 is also a gain-of-function mutation, however, its prognosis 
significance is still unclear due to its rarity [76,77]. 
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1.5.2 FLT3 inhibitors 
Because of the association between FLT3-ITD and the higher relapse rate and poor disease-
free and overall survival in AML, the effort to develop FLT3 inhibitors has been made in the 
recent decade. Nowadays, more than 20 small-molecule inhibitors targeting FLT3 have been 
reported and clinical trials to evaluate them are ongoing. The well-studied FLT3 inhibitors 
include sunitinib, tandutinib, sorafenib and PKC412 [78-81].   
PKC412 (midostaurin), the N-benzoyl derivative of staurosporine, was named after its 
characterization as an inhibitor of PKC.  It has activity not only against both FLT3-IDT and 
FLT3-TKD mutation, but also against multiple other kinases, including PDGFR and c-KIT 
[82].  In a phase I study including various solid tumors, the results showed inhibition of FLT3 
activity with 75 mg thrice daily of PKC412. In phase II clinical trials, this dose was also well 
tolerated by 20 patients with FLT3-mutant AML and resulted in a significant decrease in 
peripheral blast counts. The phase III trials combining PKC412 with standard induction and 
postremission chemotherapy is ongoing, and the preliminary results show an improved 
overall survival in younger adult patients [77,83].  
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2 AIMS OF THE STUDY 
 
The overall objective of this study is to define novel role of TERT and telomerase in cancer 
development, progression and cure, as well as the clinical implication of genetic alterations in 
TERT in cancer. More specifically, the study aims are: 
1. To determine whether FLT3-ITD regulates TERT expression in AML cells and whether 
TERT expression affects FLT3 inhibitors‟ therapeutic efficacy in AML (Paper I). 
2. To determine whether the rs2736100/rs2736098 variants in the TERT gene are associated 
with the incidence of TERT promoter mutations and HCC susceptibility (Paper II). 
3. To define whether TERT promotes HCC development by regulating DNA methylation 
(Paper III). 
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3 METHODS 
 
3.1 Patient samples (Papers I - III) 
Patients‟ peripheral blood samples were collected at the Department of Hematology, 
Karolinska University Hospital, Stockholm, Sweden. The study was approved by the 
Stockholm Regional Ethics Review Committee, and written informed consent was obtained 
from the subjects (Paper I). Two hundred and forty-five patients with HCC as well as two 
hundred and fifty-seven healthy individuals were recruited from Shandong Provincial 
Hospital and Shandong University Second Hospital, Jinan, China. Fifty-three patients with 
newly diagnosed histologically confirmed HCC were recruited from Qilu Hospital, Jinan, 
China. Tumor specimens and/or blood samples were obtained after written informed consent 
was obtained from the patients. The study was approved by the Shandong University Second 
Hospital Ethics Committee (Papers II - III). All experiments were performed in accordance 
with relevant guidelines and regulations. 
3.2 Cell lines and culture conditions (Papers I - III) 
AML cell lines HL60, MV4:11 and MOLM-13 were used in Paper I. The specific FLT3 
inhibitor PKC412 (Sigma-Aldrich, Buchs, Switzerland) was diluted in DMSO, and added 
into cells at different concentrations (0.01, 0.025, 0.05, and 0.1 μM) for various time 
periods (Paper I). HCC cell lines PLC/PRF/5 and HUH-7 were used in Paper III. The 
PIK3/AKT inhibitor LY2490024 was purchased from Millipore Sigma, and added into 
wells at 30 µM (Paper III). 
3.3 Mutation analysis of FLT3-ITD (Paper I)  
QIAamp Blood & Cell Culture DNA Kit (QIAGEN, Germany) was used to extract DNA 
from AML patients. PCR primers were fluorescently labeled with 6-FAM, HEX or NED. The 
length of amplified fragments with dye was detected by Applied Biosystems 3130XL and 
FLT3-ITD mutations were detected qualitatively by comparing it to a size standard using the 
GeneMapper Software. 
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3.4 Primary AML cell separation and culture (Paper I) 
 Leukemic cells were isolated from AML patients by Lymphoprep gradient centrifugation 
(Nycomb, Oslo, Norway) from peripheral blood and then cultured in complete medium in the 
absence or presence of PKC412 as described above. 
3.5 RNA extraction and quantitative real-time PCR (Paper I & III) 
Total cellular RNA in cells with different treatments and primary tumor tissues was 
extracted using Trizol, and RNA was reverse transcribed to cDNA. Quantitative real-time 
polymerase chain reaction (qPCR) was carried out using SYBR Green and specific primers. 
Relative expression of target mRNAs were calculated based on the CT values and 
normalized to β2m CT values. Primers used for qPCR are listed in Table 2. 
Table 2. Primers and small interference RNAs (siRNAs) used in the study 
Primers for qPCR  
β2m-F 5′-GAATTGCTATGTGTCTGGGT-3′ 
β2m-R 5′-CATCTTCAAACCTCCATGATG-3 
RASSF1A –F:  5‟- TCATCTGGGGCGTCGTG -3‟ 
RASSF1A –R:  5‟- CGTTCGTGTCCCGCTCC -3‟ 
PTEN-F:  5‟-CCGGCAGCATCAAATGTTTC-3‟ 
PTEN-R:  5‟-GTTCCACCCCTTCCATCTGC-3‟ 
DNMT3b-F 5‟-TGTTTCTGTGTGGAGTGC-3‟ 
DNMT3b-R 5‟-CAGCAATGGACTCCTCAC-3‟ 
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TERT-F 5‟-CGGAAGAGTGTCTGGAGCAA-3‟ 
TERT-R 5‟- GGATGAAGCGGAGTCTGGA-3‟ 
c-Myc-F 5′-TACCCTCTCAACGACAGCAGCTCGCCCAACTCCT-3′ 
c-Myc-R 5′-TCTTGACATTCTCCTCGGTGTCCGAGGACCT-3′ 
c-KIT-F 5′-TCATGGTCGGATCACAAAGA-3′ 
c-KIT-R 5′-AGGGGCTGCTTCCTAAAGAG-3′ 
DOK3-F 5′-GTCCCCATGGAGGAAAACTC-3′ 
DOK3-R 5′-AAGTGGTAGGGCCAGCTGTA-3′ 
SULF2-F 5′-CCGCCCAGCCCCGAAACC-3′ 
SULF2-R 5′-CTCCCGCAACAGCCACACCTT-3′ 
siRNAs 
DS NC1 Negative 
Control 
5„-CGUUAAUCGCGUAUAAUACGCGUAT-3‟  
 siPTEN 5„-AUGUGCAGUGUUGAAUCAUUUCUTC-3‟ 
 siTERT.1 5„-CAUUUUUCCUGCGCGUCAUCUCUGA-3‟ 
 siTERT.2 5„-GGUGAACUUCCCUGUAGAAGACGAG-3‟ 
siSP1.1 5„-GGUGCAAACCAACAGAUUAUCACAA-3‟ 
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siSP1.2 5„-GGUGAGAUAGUAAAACACUUAUUCC-3‟ 
Primers for Pyrosequencing 
PTEN.PCR primer F  5‟-TTGTTATTATTTTTAGGGTTGGGAA -3‟ 
PTEN.PCR primer R   5‟-Biotin-CTAAACCTACTTCTCCTCAACAACC -3‟ 
PTEN.Pyrosequencing 
primer  
5‟- GTTGGTATATTTAGGGATT -3‟ 
3.6 Western blot (Papers I & III) 
Total proteins from cells were extracted and quantified. Thirty µg of proteins were 
separated in Mini-PROTEAN TGX Gels and transferred to PVDF membranes. Membranes 
were blocked with 5% non-fat milk diluted in TBST, and then incubated with primary 
antibodies and followed by anti-mouse or rabbit secondary antibodies before imaged. 
Primary antibodies used were: AKT, p-AKT, FLT3 and p-FLT3, (Cell Signaling 
Technology, Boston, USA); β-Actin, c-MYC, Sp1 and PTEN (Santa Cruz Biotechnologies); 
TERT and DNMT3B (Abcam). β-Actin immunoblotting was performed in parallel as a 
loading control. 
3.7 Assessment of telomerase activity (Paper I) 
A protocol based on real-time telomeric repeat amplification was used to determine 
telomerase activity. Total cellular proteins were extracted using CHAPS lysis buffer. For 
each assay, 0.5 μg of protein was used for the telomerase-primer elongation with 30-min 
incubation at 30℃, which was then terminated by 5-min incubation at 95℃. The products 
containing telomeric repeats were further amplified using SYBR Green kit and detected by 
ABI7700 sequence detector.  Total cellular protein from HCC cell line HepG2 was used as 
a positive control and the serial dilutions of positive control were used as standard curve 
[84]. 
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3.8 Promoter activity assay (Papers I & III) 
The TERT promoter reporter plasmid p181wt harboring the core promoter sequence of the 
hTERT 5′-flanking region and its mutant variant (p181MYC−) with c-MYC motifs (E-
boxes) deletion were described previously [85,86]. These two plasmids were transfected 
into MV4,11 and MOLM-13 cells with Lipofectamine2000 (Life Technology) according to 
the manufacturer’s protocol in the absence or presence of  PKC412. The cells were lysed 
and the luciferase activity was determined using a dual-luciferase reporter assay system 
(Promega, WI) 24 h after the transfection (Paper I). 
The DNMT3B reporter construct contains the human DNMT3B promoter sequence (-469 - 
+260) from Shanghai Integrated Biotech Solutions (Shanghai, China). DNMT3B promoter 
plasmids were transfected into cells together with the control or TERT and/or Sp1 expression 
vectors using Lipofectamine2000, and the luciferase activity was determined using a dual 
luciferase reporter assay system (Promega, Madison, WI) 48 h post-transfection (Paper III). 
3.9 Puro. Cre-TERT promoter-driven GFP plasmid and Lenti-III-HA-
GFP-TERT vectors (Paper I) 
The h3.4k-GFP plasmid was obtained from Dr. Pei-Rong Huang (National Taiwan 
University), which contained 3.4-kb TERT promoter (+ 1 to − 3405, ATG as + 1) located 
just upstream of GFP gene. To construct pLenti-III-HA-GFP-TERT vector, a 4.5-kb GFP-
TERT fragment was cut from pBabe-hygro-GFP-TERT (addgene) and inserted into pLenti-
III-HA (Applied Biological Materials Inc, BC, Canadia). A control plasmid (pLenti-BMN-
GFP) was kindly provided by Rudbeck Laboratory, Uppsala University. The vectors were 
packaged into viral particles used for infecting AML cells to make cells with TERT 
promoter-driven GFP or with TERT over expression. 
3.10 Cell cycle and apoptosis analyses (Paper I) 
Stable TERT-over-expressed MOLM-13 cells and their control counterparts with pBMN 
were treated with 0.1 μM PKC412 for 24 h. The cells were fixed with ice cold 70% ethanol 
at +4 °C overnight, and stained with propidium iodide (50 μg/ml) in the presence of  
RNAse A (0.5 μg). Apoptotic cells and cell cycle distribution were determined using flow 
cytometry. 
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3.11 cDNA array (Paper III) 
Stable TERT-over-expressed MOLM-13 cells and their counterparts with control pBMN 
were treated with DMSO or 0.1 μM PKC412 for 12 h. Total RNA was extracted for 
affymetrix Human Gene 1.0 ST Array. The differential gene expression between DMSO- 
and PKC412-treated cells with or without ectopic TERT expression was then analyzed. 
3.12 DNA extraction and Sanger sequencing of the TERT promoter 
and CTNNB1 gene (Paper II) 
Genomic DNA was extracted using QIAGEN DNA extraction kits. DNA extracted from 
HCC tumors was used for Sanger sequencing to analyze CTNNB1 gene mutations and 
TERT promoter mutations.  
Sanger sequencing uses ssDNA as template and determines the sequence according to 
different length and end of amplified fragments [87]. Both deoxy-ribonucleoside 
triphosphate (dNTP) and dideoxyribonucleoside triphosphate (ddNTP) are added in the 
PCR system. The amplification will continue with a dNTP binding to the template, while 
the amplification will come to an end with ddNTP, which is incapable of binding to next 
nucleotide [88]. The binding of dNTP or ddNTP is random and therefore the amplification 
ends at different positions. Since four ddNTPs are labeled with different fluorescence dyes, 
integrating the termination signals can give the sequence of the template [89].   
The mutation occurring at positions 124 and 146 bp upstream of the ATG site in the TERT 
core promoter were named as C228T and C250T. The primer pair for the TERT promoter 
sequencing was previously described: 5′-CAC CCG TCC TGC CCC TTC ACC TT-3′ 
(forward) and 5′-GGC TTC CCA CGT GCG CAG CAG GA-3′ (reverse). The CTNNB1 
gene hotspot mutations occur in exon 3 and the primers used to sequence this region are 
listed as follows: 5′-GGG TAT TTG AAG TAT ACC ATA C-3′ (forward) and 5′-TGG 
TCC TCG TCA TTT AGC AG-3′ (reverse). All the mutations were verified by sequencing 
from both directions [10,90-92]. 
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3.13 The TERT rs2736100 (AC) AND rs2736098 (TC) genotyping 
(Paper II) 
The TERT rs2736098 (TC) and rs2736100 (AC) were genotyped using pre-designed 
TaqMan SNP genotyping assay kits on an ABI PRISM 7900 HT Sequence Detection 
System (Applied Biosystems), as described [93,94]. Both positive and negative controls 
were included in all assays and the running condition was as follows: 95°C for 10 min, 
followed by 40 cycles of 92°C for 15 sec and 60°C for 1 min. 
3.14 Small interference RNA (siRNA) transfection (Paper III) 
siRNAs targeting TERT, Sp1, and PTEN were purchased from (Thermo Fisher Scientific) 
and Integrated DNA Technologies (IDT, Leuven, Belgium). Cells were transfected with 
siRNAs using Lipofactamine2000 (Thermo Fisher Scientific) according to the protocol 
provided. Cells were harvested for analyses 72 h post-transfection. siRNAs used in this study 
are listed in Table 2. 
3.15 Plasmid transfection (Paper III) 
TERT and Sp1 expression plasmids were kindly provided by Professor. R. Weinberg 
(Massachusetts Institute of Technology) and Doctor R. Tjian (Howard Hughes Medical 
Institute, Ashburn), respectively. The DNMT3B expression plasmid was purchased from 
AdeGene. Lipofactamine2000 (Thermo Fisher Scientific) was used for transfection according 
to the protocol provided. 
3.16 Colony formation assay (Paper III) 
HCC cells under different treatment conditions were seeded into six well-plates (1 000 
cells/well) and incubated for 10 – 14 days. Plates were stained with Giemsa and the number 
of colonies with more than 50 cells was counted. The PIK3/AKT inhibitor LY2490024 was 
purchased from Millipore Sigma, and added into wells at 30 µM when TERT over-expressed 
cells were seeded. 
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3.17 DNA methylation assessments (Paper III) 
Luminometric Methylation Assay (LUMA) and bisulfite pyrosequencing were used to 
determine global and PTEN promoter methylation, respectively. The LUMA assay has 
previously been described and exploits methylation sensitive and insensitive restriction 
enzymes followed by detection with Pyrosequencing [95,96]. Briefly, each DNA sample was 
subjected to two separate digestions, with HpaII + EcoRI and MspI + EcoRI. The digested 
DNA was then subjected to polymerase extension assays using Pyrosequencing. The level of 
cytosine methylation was finally determined by comparing the ratio of HpaII to MspI 
cleavages in the various samples. Pyrosequencing was previously described [97,98]. Briefly, 
genomic DNA was bisulfite-converted, and PCR amplification performed using PTEN 
promoter specific primers [99]. A biotin-labeled primer (reverse primer) was used to purify 
the PCR product by use of streptavidin-coated Sepharose beads (GE Healthcare, UK). PCR 
products were bound to Sepharose beads, purified, washed, denatured, and washed again. 
Then sequencing primer was annealed to the purified single-stranded PCR product and the 
Pyrosequencing was performed in a PyroMark Q96 (Qiagen) according to the manufacturer‟s 
instructions. The primers for PCR and sequencing are listed in Table 2.  
3.18 The Cancer Genome Atlas (TCGA) dataset (Paper III) 
The TCGA Research Network is available at http://cancergenome.nih.gov/. The datasets for 
HCC cases within the TCGA database were downloaded via Memorial Sloan Kettering 
Cancer Center cBioPortal for cancer genomics in January 2018 [100,101]. 
3.19 Statistical analyses (Papers I - III) 
Mann-Whitney U-test was performed to examine the difference in DNA methylation as 
determined using LUMA and Pyrosequencing (Paper III). All other comparisons between 
control and treated cells were analyzed using Student‟s T-test or one-way ANOVA followed 
by LSD test (Paper I & III). Correlation between TERT and DNMT3B expression in HCC 
tumors was assessed using Pearson test. Differences in survival were compared with the log-
rank test. Overall survival was visualized with Kaplan-Meier plots (Paper III). Chi-square (χ2) 
test was used to compare sex distribution between HCC patients and healthy controls. χ2 test 
or Student‟s T-test was used to analyze the differences in clinico-pathological variables 
between HCC patients with wild type or mutated TERT promoter, respectively. χ2 test was 
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used to evaluate the distribution differences of selected variables and alleles of the TERT 
rs2736098 and rs2736100 between patients and healthy controls. Hardy–Weinberg 
equilibrium of the genotype distribution among the controls was tested by a goodness-of-fit 
χ2 test. Odds ratios (OR) and their 95% confidence interval (CI) were estimated using 
unconditional univariate and multivariate logistic regression analyses for risk of HCC or 
tumors with and without TERT promoter mutation (Paper II). All the tests were two-tailed. P 
values <0.05 were considered significant. 
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4 RESULTS & DISCUSSION 
 
4.1 MYC-dependent down-regulation of telomerase by FLT3 
inhibitors is required for their therapeutic efficacy on AML 
(Paper I) 
4.1.1 PKC412 down-regulated TERT expression and TERT promoter activity 
in FLT3ITD-carrying AML cells 
PKC412, a specific FLT3ITD inhibitor, was used in this study. In AML cell lines MV4, 11 
and MOLM-13, which carry FLT3ITD mutations, PKC412 inhibited FLT3 phosphorylation 
and activity in both time- and dose-dependent manners. TERT mRNA expression was 
down-regulated in MV4, 11, MOLM-13 and primary FLT3ITD-positive AML cells after 
PKC412 treatment. The qPCR results showed that PKC412 inhibited TERT mRNA 
expression also in a dose-dependent manner. To confirm the role of FLT3ITD mutations in 
PKC412-mediated down-regulation of TERT expression, two wild-type FLT3-carrying cell 
lines HL60 and HeLa were treated with PKC412, however, there were no detectable 
changes in TERT mRNA level, which suggested that PKC412 inhibited TERT expression 
via FLT3ITD. A significantly diminished telomerase activity was detected in MV4, 11 and 
MOLM-13 as well 24h after treated with PKC412. 
4.1.2 PKC412 inhibited TERT transcription in a MYC-dependent way 
To determine the underlying mechanism, a GFP expression vector driven by a 3.4-kb-long 
TERT promoter was constructed and transfected into MV4, 11 and MOLM-13 cells and the 
cells were then treated with PKC412. PKC412 led to reduced GFP+ cells compared to 
DMSO. A core TERT promoter reporter construct (p181) was transfected into the same 
cells followed by DMSO or PKC412 treatment. The luciferase activity driven by p181 was 
significantly inhibited in these cells after PKC412 treatment. 
PKC412 treatment led to diminished c-MYC mRNA and protein expression in MV4, 11 
and MOLM-13 cells. Because c-MYC is a well-established TF regulating TERT expression 
[102], our hypothesis is that FLT3ITD regulates TERT transcription via c-MYC. Wild-type 
p181 vector and its counterpart with MYC binding motif-deletion were transfected into the 
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same cell lines, respectively. When these cells were treated with PKC412, wild-type TERT 
promoter activity was down-regulated compared to that in DMSO-treated control cells. In 
contrast, no difference between DMSO and PKC412 treatment was observed when cells 
were transfected with the MYC binding site-deleted p181 vector. 
4.1.3 The attenuation of PKC412-mediated AML cell apoptosis by ectopic 
TERT expression  
To explore whether TERT expression was associated with the PKC412 effect in AML cell 
killing, a variant subline of MOLM-13 with ectopic TERT expression (MOLM-13-hTERT) 
and the control subline with empty vectors (MOLM-13-pBMN) were made. IC50 was 17.2 
and 34.1 μM for MOLM-13-pBMN and MOLM-13-TERT, respectively. The viability was 
assessed by incubating these two sublines with or without PKC412 (0.0125 μM) for 
different time periods. The viability in MOLM-13-TERT cells was significantly higher than 
that in MOLM-13-pBMN at all the time points (P = 0.009). Almost all MOLM-13-pBMN 
cells were dead by 120 h. The results from flow cytometry revealed that the ectopic TERT 
expression significantly attenuated apoptosis mediated by PKC412, which was consistent 
with the cell viability results. 
4.1.4 The enhanced activity of alternative tyrosine kinase signaling 
pathways and AKT mediated by TERT in the presence of PKC412 
Comparing the gene expression profiles between MOLM-13-pBMN and MOLM-13-
hTERT cells treated with DMSO or PKC412, we found that ectopic TERT expression 
contributed to the activation of alternative tyrosine kinase pathways in the presence of 
PKC412. c-KIT, another tyrosine kinase receptor, and SULF2, an activator in the PDGF 
signaling pathway, were up-regulated;  DOC3, a negative regulator of the RAS signaling 
pathway was repressed (Figure 2). 
Moreover, in PKC412-treated cells, ectopic TERT expression also increased the 
phosphorylation and activation of AKT, a well-studied downstream effector in tyrosine 
kinase signaling pathways which promotes cell survival [103]. 
In summary, this study demonstrated that FLT3ITD mutations play an important role in 
constitutive TERT expression, and the FLT3 specific inhibitor PKC412 contributes to AML 
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cells killing by suppressing TERT expression. PKC412 inhibited both FLT3 activation and 
TERT expression, and ectopic TERT expression rescued the PKC412-mediated apoptosis 
of MOLM-13 cells. Furthermore, we demonstrated that the induction of TERT transcription 
by FLT3ITD was MYC-dependent. It has been reported that TERT can contribute to cell 
survival by up-regulating growth factors and pro-survival factors through its telomere 
lengthening-independent function [104-106]. In this study we found ectopic TERT 
expression enhanced alternative tyrosine kinase signaling pathways as well as the 
downstream effector AKT. Taken together, TERT may play an important role in the 
resistance to AML-targeted therapy, and the positive feedback between FLT3ITD and 
telomerase may shed light on AML pathogenesis and therapy. 
 
 
Figure 2. TERT stimulates the FLT3 downstream effectors and alternative tyrosine kinase 
pathways in the presence of PKC412, and the schematic of c-KIT, DOC3, and SULF2 as 
regulators of the FLT3 and other tyrosine kinase signaling pathways. 
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4.2 The TERT promoter mutation incidence is modified by 
germline TERT rs2736098 and rs2736100 polymorphisms in 
HCC (Paper II) 
4.2.1 TERT promoter mutations and their relation to CTNNB1 mutations and 
clinico-pathological variables in HCCs  
Tumor DNA from 200 HCC patients was extracted and sequenced to identify TERT 
promoter mutations, among which 190 were evaluable (Figure 3). The results showed 57 of 
190 (30%) tumors carrying TERT promoter mutations, and the frequency of C228T was 
higher (50 out of 57; 88%) than that of C250T (7 out of 57; 12%). It is reported that the 
CTNNB1 gene mutation occurs frequently and is associated with TERT promoter mutations 
in HCC [107,108].  DNA from 81 HCC tumors was used for Sanger sequencing to assess 
the hotspot mutations in CTNNB1 exon 3. The sequencing was successful in 70 of them, 
among which 17 (24%) tumors carried mutations. No association between CTNNB1 
mutations and TERT promoter mutations was observed in these HCC tumors.  
 
Figure 3. Identification of TERT promoter mutations (C250T and C228T) in HCC 
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We further analyzed the relationship between TERT promoter mutations and clinico-
pathological variables, and no significant differences were observed in sex, age, α-
fetoprotein levels, liver cirrhosis, HBV infection, tumor sizes, differentiation status and 
metastasis. 
4.2.2 The association between TERT genetic variants and TERT promoter 
mutations in HCC  
Accumulating studies showed that TERT rs2736098 and rs2736100 variants are associated 
with cancer risk. We thus carried out TERT rs2736098 (TC) and rs2736100 (AC) 
genotyping. For rs2736098, data were available in 231 HCC patients and 240 healthy 
controls; for rs2736100, data were available in 201 HCC patients and 237 healthy controls. 
When comparing genotype and allele frequencies of the two variants between patients and 
healthy controls, we found that HCC patients exhibited a significantly lower frequency of 
rs2736100_CC genotype. 
Since it is reported that both rs2736098 and rs2736100 variants are capable of regulating 
TERT expression and telomerase activity [109-111], next we sought to define if there is a 
link between these two TERT genetic variants and TERT promoter mutations. When 
comparing HCC patients bearing TERT promoter mutations and healthy controls, we found 
that the frequencies of rs2736098_TT and rs2736100_CC were significantly lower in the 
group with mutations (Table 3). When comparing HCC patients with wild-type and mutant 
TERT promoters, similar distributions were observed: the group with mutations exhibited 
significantly lower frequencies of both rs2736098_TT and rs2736100_CC (Table 4). 
According to the result of linkage disequilibrium analysis, the association between 
rs2736098 and rs2736100 is non-significant in the Han Chinese population. 
In summary, we observed a negative association between TERT promoter mutations and 
rs2736098_TT/ rs2736100_CC. It is known that both C228T and C250T TERT promoter 
mutations generate new ETS binding sites, thereby activating TERT transcription, and 
tumors with shorter telomere are prone to undergo TERT promoter mutations [10,112-115]. 
However, studies have shown that rs2736100_CC and rs2736098_TT have opposite effects 
on TERT transcription. rs2736098_TT tends to repress TERT transcription and telomere 
elongation, while rs2736100_CC has been shown to be associated with higher TERT 
  
28 
 
expression and longer telomeres. The lower frequency of rs2736100_CC in patients with 
HCC tumors with TERT promoter mutations can be explained by genetic stress, since the 
higher TERT expression resulting from rs2736100_CC gives HCC patients less stress for 
telomerase activation and therefore TERT promoter mutations. In contrast, the lower 
frequency of rs2736098_TT in HCC patients with TERT promoter mutations cannot be 
explained by this genetic stress. 
We failed to find an association between TERT promoter mutations and clinico-
pathological variables including sex, age, α-fetoprotein levels, liver cirrhosis, HBV 
infection, tumor sizes, differentiation status and metastasis as reported previously 
[107,108,116-122]. We found that TERT promoter mutations and CTNNB1 mutations were 
independent of each other, contrasting to previously published results [107,108].  
Table 3. TERT promoter mutations and association with rs2736100 and rs2736098 in 
HCC patients 
Genotype Odds Cases Healthy 
controls 
ratio (95% CI) P 
rs2736098      
wt TERT promoter vs controls  128 (100%)  
 
240 (100%)  
 
  
TT  13 (10.1)  
 
31 (12.9 ) 1.0 (Ref.)  
CT  61 (47.7)  
 
115 (47.9 ) 1.265 (0.617–2.594) 0.643 
CC  54 (42.2)  
 
94 (39.2 ) 1.370 (0.661–2.840) 0.504  
CT + CC  115 (89.9)  
 
209 (87.1) 1.310 (0.660–2.607) 0.543  
mt TERT promoter vs controls  55 (100%)  
 
240 (100%)   
TT  2 (3.6)  
 
31 (12.9 ) 1.0 (Ref.)  
CT  40 (72.7)  
 
115 (47.9 ) 5.391 (1.234–23.553) 0.025  
CC  13 (23.7)  
 
94 (39.2) 2.144 (0.458–10.030) 0.505  
CT + CC  53 (96.4)  
 
209 (87.1) 3.931 (0.912–16.948) 0.083  
rs2736100      
wt TERT promoter vs controls  114 (100%)  
 
237 (100%)   
AA  38 (33.3)  
 
69 (29.1)  1.0 (Ref.)   
CA  52 (45.6)  
 
108 (45.6)  1.141 (0.683–1.916)  0.705  
CC  24 (21.1)  
 
60 (25.3)  0.726 (0.392–1.346)  0.389  
AA + AC  90 (78.9)  
 
177 (74.7)  1.0 (Ref.)   
CC 24 (21.1)  
 
60 (25.3)  0.787 ( 0.460–1.346)  0.457  
mt TERT promoter vs controls 52 (100%)  
 
237 (100%)    
AA  15 (28.8)  
 
69 (29.1)  1.0 (Ref.)   
CA  34 (65.4)  
 
108 (45.6)  1.448 (0.735–2.854)  0.389  
CC  3 (5.8)   
 
60 (25.3) 0.230 (0.0635–0.833)  0.032  
AA + AC  49 (94.2)  
 
177 (74.7)  1.0 (Ref.)   
CC 3 (5.8)  
 
60 (25.3)  0.181 (0.0543–0.601)  0.004  
HCC, Hepatocellular carcinoma; CI, confidence interval.  
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Table 4. rs2736098 and rs2736100 genotype frequency in HCC patients bearing 
wt and mutant TERT promoter in tumors  
 wt  
 
mutant  P value  
rs2736098  
 
128 (100%)  55 (100%)   
TT  
 
13 (10.1)  2 (3.6)   
CT  
 
61 (47.7)  40 (72.7)   
CC  
 
54 (42.2)  13 (23.7)  0.007  
rs2736100  
 
114 (100%)  52 (100%)   
AA  
 
38 (33.3)  15 (28.8)   
CA  
 
52 (45.6)  34 (65.4)   
CC  
 
24 (21.1)  3 (5.8)  0.018  
HCC, hepatocellular carcinoma.  
 
4.3 TERT is required for DNMT3B expression/ aberrant DNA 
methylation phenotype and AKT activation in HCC (Paper III) 
4.3.1 TERT regulates DNMT3B expression and the downstream tumor 
suppressors in HCC cells  
TERT is known to be important in tumorigenesis by both canonical telomere-lengthening 
function and its activities independent of telomere stabilization. The aberrant DNA 
methylation is another key factor contributing to human malignancies [123,124]. In this study, 
we wanted to determine the potential link between TERT and cancer-specific DNA 
methylation. DNMT3B is a member of DNMTs and has been reported to promote HCC 
progression [125]. Our results showed that in HCC cell lines PLC/PRF/5 and HUH-7, TERT 
depletion down-regulated DNMT3B expression while TERT over-expression up-regulated 
DNMT3B expression at both mRNA and protein levels. Consistent with the results in HCC 
cell lines, a positive correlation was observed between TERT and DNMT3B mRNA 
expression in 53 primary HCC tumors. 
DNMTs contribute to tumorigenesis by repressing downstream tumor suppressors, and 
therefore we further assessed the expression of PTEN and RASSF1A, two well-studied 
TSGs repressed by DNMT3B-mediated promoter hypermethylation [39,40,126,127]. TERT 
depletion increased, whereas ectopic TERT inhibited PTEN expression at both mRNA and 
protein levels. Moreover, the over-expression of DNMT3B rescued the de-repression of 
PTEN resulting from TERT depletion at both mRNA and protein levels. Similar changes of 
RASSF1A transcripts were observed in the experiments above. 
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4.3.2 TERT inhibition leads to the PTEN promoter demethylation and global 
decline in DNA methylation in HCC cells 
To see whether TERT regulates DNMT3B downstream tumor suppressors by affecting 
their promoter methylation, we first performed Pyrosequencing to examine the methylation 
status of the PTEN promoter region in PLC/PRF/5. TERT depletion led to a significant 
demethylation at 3 of 9 CpG positions sequenced successfully in the PTEN promoter. 
Beyond that, we further performed LUMA to assess global methylation in PLC/PRF/5 after 
TERT knock-down. The results showed a significant decline in global methylation compared 
to the control counterparts. Taken together, TERT plays an important role in the aberrant 
methylation in HCC cells. 
4.3.3 TERT cooperates with Sp1 to stimulate DNMT3B promoter activity 
It is reported that the TF Sp1 can bind to the DNMT3B promoter and stimulate its 
transcription [128]. Studies have also shown that TERT can interact with Sp1 as a co-factor 
to facilitate Sp1 target transcription [32]. We hypothesize that this may be the case in TERT-
mediated DNMT3B expression. As expected, the ectopic expression of Sp1 increased 
abundance of DNMT3B while the depletion of Sp1 decreased DNMT3B expression in both 
PLC/PRF/5 and HUH-7. Moreover, both the gain and loss-function assays of Sp1 revealed 
that PTEN expression was altered in the opposite manner to DNMT3B. Over-expression of 
Sp1 rescued the decreased DNMT3B expression resulting from TERT depletion. We further 
constructed the reporter plasmid containing DNMT3B promoter sequence. When co-
transfected cells with TERT or Sp1 expression vector alone, only a slight increase in 
DNMT3B promoter activity was observed, whereas DNMT3B promoter activity was 
significantly increased when co-transfected with both TERT and Sp1 expression vectors. The 
results suggested that TERT regulates DNMT3B transcription by cooperating with Sp1. 
4.3.4 TERT-DNMT3B-PTEN-AKT axis in HCC  
According to the results presented in Paper I, TERT plays a positive role in AKT activation in 
leukemic cells. We thus examined whether it was the same in HCC cells. PTEN is a tumor 
suppressor, and negatively regulates the PI3K/AKT signaling pathway [129]. Consistently, 
TERT over-expression enhanced while its depletion diminished pAKT abundance. 
Furthermore, the down-regulation of pAKT mediated by TERT knock-down was rescued 
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when blocking PTEN expression using PTEN specific siRNA. Taken together, the results 
reveal a TERT-DNMT3B-PTEN-AKT axis in HCC cells. 
We further evaluated the functional effect of this axis by assessing clonogenic formation of 
HCC cells. Consistent with previous studies reporting that TERT promotes cancer cell 
survival and proliferation, TERT depletion led to a significant decline in the number of 
colonies. The over-expression of either DMT3B or its TF Sp1 restored the decline. Moreover, 
a blockade of AKT activity by its inhibitor LY2940024 abolished the enhancement of 
clonogenic potential mediated by TERT over-expression. 
We also sought to determine the clinical relevance of TERT-DNMT3B-PTEN-AKT axis. 
The analysis in 380 HCC patients from the TCGA database revealed that higher levels of 
TERT and DNMT3B expression both predict shorter survival, which suggests a promoting 
effect of this axis on HCC disease progression. 
In summary, we demonstrated a novel telomere lengthening-independent role of TERT by 
showing a link between TERT and aberrant DNA methylation in HCC.  Mechanistically, 
TERT promotes DNMT3B transcription by cooperating with Sp1, thereby contributing to the 
maintenance of global DNA hypermethylation as well as gene-specific hypermethylation in 
HCC cells. Our results reveal that PTEN, one of the well-studied DNMT3B downstream 
tumor suppressors, is regulated by TERT via promoter DNA methylation. In addition, we 
found the TERT-mediated PTEN repression enhances AKT activity, which in turn promotes 
cell survival and proliferation. While previous studies mainly focused on the role of AKT in 
TERT phosphorylation and stabilization, our results indicate a positive feedback loop 
between TERT and AKT. Taken together, the TERT-DNMT3B-PTEN-AKT axis may 
greatly drive HCC pathogenesis and be the hub for three oncogenic signaling cascades and 
targets for cancer therapy (Figure 4). 
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Figure 4. TERT-DNMT3B-PTEN-AKT axis in HCC progression. 
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5 SUMMARY& CONCLUSIONS 
 
1. The FLT3 inhibitor PKC412 represses TERT expression and telomerase activity in AML 
cells carrying FLT3ITD mutations, and this effect is MYC-dependent. On the other hand, 
ectopic TERT expression attenuates the PKC412-mediated apoptosis of AML cells,  and 
activates alternative tyrosine kinase signaling pathways as well as downstream effector 
AKT. The findings indicate a link between FLT3ITD mutations and telomerase.  
Moreover, our study also demonstrated that TERT is required for therapeutic efficacy of 
PKC412 in AML and TERT confers resistance to the PKC412 targeted AML therapy 
(Paper I).  
2. HCC patients bearing tumors with mutant TERT promoter showed lower frequencies of 
rs2736098_TT and rs2736100_CC compared to wild type TERT promoter-carrying HCC 
patients or healthy controls. This indicates a negative association between TERT 
promoter mutations and these two genotypes, and also reveals the effect of germline 
TERT genetic background on TERT promoter mutations occurrence (Paper II). 
3. TERT promotes DNMT3B transcription by cooperating with the TF Sp1, thereby 
contributing to the maintenance of hypermethylation and the repression of downstream 
tumor suppressors PTEN and RASSF1A. TERT depletion led to significant 
demethylation in the PTEN promoter as well as a reduced global DNA methylation. The 
restoration of PTEN expression mediated by TERT depletion inhibited AKT activity, 
which forms a positive feedback between AKT and TERT. Higher levels of TERT and 
DNMT3B expression predicted significantly shorter survival in HCC patients. Taken 
together, we identified the TERT-DNMT3B-PTEN-AKT axis in HCC cells which 
promotes HCC progression via aberrant DNA methylation (Paper III). 
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